NCT02067936

Brief Summary

The investigators study whether four equipotent combinations of propofol and remifentanil (as predicted by interaction models for "tolerance of laryngoscopy") result in identical haemodynamic conditions, independent of their relative different balance between the concentration of propofol and remifentanil.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
87

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2014

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

February 3, 2014

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 20, 2014

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2015

Completed
Last Updated

December 4, 2015

Status Verified

December 1, 2015

Enrollment Period

1.6 years

First QC Date

February 3, 2014

Last Update Submit

December 3, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Blood pressure

    Continuously stored on a laptop (systolic, diastolic and mean blood pressure over time) using a Philips Non Invasive Blood Pressure measurements every minute and a Nexfin monitor (continuous non invasive blood pressure measurement)

    From start drug till intubation which will take on average 15 minutes of measurement

Secondary Outcomes (5)

  • Electro Encephalographic derived indices of anesthetic depth

    From start first drug till intubation, which will take on average 15 minutes of measurement

  • Cerebral and tissue oxygenation

    From start drug till intubation, which will take on average 15 minutes of measurement

  • Heart rate

    From start first drug till intubation, which will take on average 15 minutes of measurement

  • Probability of tolerance to laryngoscopy

    one minute before laryngoscopy till three minutes after

  • Cardiac index

    From start first drug till intubation, which will take on average 15 minutes of measurement

Study Arms (4)

Group A propofol + remifentanil

ACTIVE COMPARATOR

Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model

Drug: Group A propofol + remifentanil

Group B propofol + remifentanil

ACTIVE COMPARATOR

Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model

Drug: Group B propofol + remifentanil

Group C propofol + remifentanil

ACTIVE COMPARATOR

propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model

Drug: Group C propofol + remifentanil

group D propofol + remifentanil

ACTIVE COMPARATOR

propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model

Drug: group D propofol + remifentanil

Interventions

Predicted TOL90% according to Bouillon model

Also known as: propofol highest dose + remifentanil lowest dose
Group A propofol + remifentanil

TOL 90% according to the Bouillon interaction model

Also known as: Propofol intermediate high+ remifentanil intermediate low
Group B propofol + remifentanil

TOL 90% according to the Bouillon interaction model

Also known as: propofol intermediate low+remifentanil intermediate high
Group C propofol + remifentanil

TOL 90% according to the Bouillon interaction model

Also known as: Propofol lowest dose+ remifentanil highest
group D propofol + remifentanil

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Written informed consent
  • General anesthesia required for the procedure
  • Age: 18 years and older
  • American Society of Anesthesiologists (ASA) physical status I to III

You may not qualify if:

  • Refusal to participate in this study
  • Contra-indications for the use of propofol or remifentanil
  • BMI \> 35 kg/m2
  • Central nervous system disorders (i.e. cerebrovascular accident, dementia, seizures, psychiatric disorders)
  • Relevant hepatic disease (Child B or higher)
  • Regular use of medication that affects the central nervous system (i.e. benzodiazepines, antidepressants, antipsychotics, antiepileptic drugs)
  • Use of alpha-agonists or beta-blockers
  • Overt signs of alcohol abuse
  • Use of preoperative benzodiazepines (on the day of the study)
  • Beta blockers eye drips
  • Overt signs of Drugs abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center Groningen

Groningen, Provincie Groningen, 9713EZ, Netherlands

Location

MeSH Terms

Interventions

Remifentanil

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Hugo EM Vereecke, MD, PhD

    University Hospital Medical center, university of groningen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

February 3, 2014

First Posted

February 20, 2014

Study Start

February 1, 2014

Primary Completion

September 1, 2015

Study Completion

September 1, 2015

Last Updated

December 4, 2015

Record last verified: 2015-12

Locations